Werewolf Therapeutics HOWL Income Statement (2020-2026)

NASDAQ HOWL
$0.43 +0.02 (+4.47%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
27.57M18.45M27.65M28.46M30.74M31.52M35.34M35.64M35.66M39.11M43.28M43.70M43.72M44.83M44.83M45.34M47.27M48.60M48.60M48.60M
Revenue & cost
Revenue (Quarter)
4.15M4.97M7.28M4.46M8.08M5.90M1.46M0.74M1.14M0.01M21.00M
Operating items
Research & Development (Quarter)
9.79M13.40M10.95M13.89M13.07M15.86M11.71M9.58M10.84M9.65M12.91M15.27M12.53M15.73M13.12M13.14M11.63M6.93M8.18M6.16M
Selling, General & Administrative (Quarter)
4.01M4.48M4.42M5.23M4.44M4.60M4.98M4.57M4.31M4.81M5.00M4.83M4.60M4.62M4.87M4.40M4.09M2.48M5.09M7.68M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
13.79M17.88M15.37M19.12M17.51M20.46M16.69M14.15M15.15M14.46M17.90M20.10M17.12M20.35M17.99M17.54M15.73M9.42M13.27M13.84M
Operating Income (Quarter)
-13.79M-17.88M-15.37M-14.97M-12.54M-13.18M-12.22M-6.07M-9.25M-12.96M-17.16M-18.96M-17.12M-20.35M-17.99M-17.54M-15.73M-9.42M-13.27M7.16M
EBIT (Quarter)
-13.79M-17.88M-15.37M-14.97M-12.54M-13.18M-12.22M-6.07M-9.25M-12.96M-17.16M-18.96M-17.12M-20.35M-17.99M-17.54M-15.73M-9.42M-13.27M7.16M
Non-operating items
Interest & Investment Income (Quarter)
0.05M-0.03M0.04M0.10M0.59M1.18M1.52M1.95M1.97M1.98M1.97M1.79M1.60M1.31M1.00M0.85M0.70M0.56M0.43M0.28M
Other Non Operating Income (Quarter)
-0.02M-0.02M0.28M0.00M0.07M-1.11M-0.03M-0.01M-0.00M-0.60M-2.26M0.17M0.01M2.02M0.67M-3.35M
Non Operating Income (Quarter)
0.04M0.01M0.02M0.38M0.60M1.25M0.24M0.97M0.97M0.96M0.97M1.71M0.45M-0.05M-0.10M-0.44M-0.64M1.04M-0.26M-3.49M
Net income details
EBT (Quarter)
-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-19.59M-17.37M-11.78M-14.21M6.96M
Profit After Tax (Quarter)
-13.76M-17.87M-15.34M-14.59M-11.94M-11.93M-11.98M-5.10M-8.29M-12.00M-16.19M-17.25M-16.67M-20.40M-18.09M-17.98M-16.37M-8.38M-13.53M3.67M
Income from Continuing Operations (Quarter)
-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-19.59M-17.37M-11.78M-14.21M6.96M
Consolidated Net Income (Quarter)
-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-19.59M-17.37M-11.78M-14.21M6.96M
Income towards Parent Company (Quarter)
-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-19.59M-17.37M-11.78M-14.21M6.96M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-13.76M-17.87M-15.34M-14.59M-11.94M-11.93M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-19.59M-17.37M-11.78M-14.21M6.96M
Additional items
EPS (Basic) (Quarter)
-0.51-0.97-0.56-0.53-0.40-0.41-0.31-0.14-0.23-0.34-0.39-0.42-0.38-0.47-0.41-0.44-0.38-0.26-0.290.14
EPS (Diluted) (Quarter)
-0.51-0.97-0.56-0.53-0.40-0.41-0.31-0.14-0.23-0.34-0.39-0.42-0.38-0.46-0.41-0.44-0.38-0.25-0.290.14
Shares Outstanding (Quarter)
27.19M18.45M27.39M27.52M29.76M28.86M34.78M35.56M35.65M35.65M41.61M43.52M43.70M43.33M44.83M44.98M45.80M46.02M48.60M48.60M
Shares Outstanding (Diluted) (Quarter)
27.19M18.45M27.39M27.52M29.76M28.86M34.78M35.56M35.65M35.65M41.61M44.04M43.70M43.86M44.83M44.98M45.80M46.81M49.39M48.60M
EBITDA (Quarter)
-13.79M-17.88M-15.37M-14.97M-12.54M-13.18M-12.22M-6.07M-9.25M-12.96M-17.16M-18.96M-17.12M-20.35M-17.99M-17.54M-15.73M-9.42M-13.27M7.16M
Interest Expenses (Quarter)
0.17M0.95M1.00M1.01M1.00M1.14M1.24M1.27M1.26M2.90M2.34M2.92M1.37M0.47M